LAG3 and cancer: Antibodies aimed at blocking the LAG-3/MHC-II interaction are being tested in five active cancer immunotherapy clinical trials (NCT03365791, NCT03499899, NCT02460224, NCT02061761, NCT02658981) and 15 more are currently recruiting at the time of publication [19].